Active, Not Recruiting
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618
- Conditions
- Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +9 more
- Locations
-
- Clinical Research Center of Alabama Birmingham, Alabama, United States
- Saguaro Dermatology Phoenix, Arizona, United States
- National Jewish Health Denver, Colorado, United States
- Encore Medical Research, Llc Hollywood Hollywood, Florida, United States